Agilent PD-L1 IHC 28-8 pharmDx Receives CE-IVD Mark as a Companion Diagnostic Test in Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Agilent Technologies, Inc. (A)
Last agilent technologies, inc. earnings: 2/18 04:05 pm
Check Earnings Report
US:NYSE Investor Relations:
investor.agilent.com
Company Research
Source: Business Wire
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to guide options for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal cancers.Gastric (stomach) cancer is the fifth most common cancer and the fourth leading cause of cancer death worldwide, with over 1,000,000 new cases and approximately 770,000 deaths in 2020.1 Esophageal cancer is the seventh most common cancer and the sixth leading cause of death from cancer worldwide, with approximately 600,000 new cases and over 540,000 deaths in 2020. 1 Together with cancers of the gastroesophageal junction, they constitute an important – and growing – global health concern.PD-L1 is a critical biomarker for response to anti-PD-1 therapies, including the immunotherapeutic agent OPDIVO® (nivolumab). When used in conjunction with the PD-L1 IHC 28-8 pharm
Show less
Read more
Impact Snapshot
Event Time:
A
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
A alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
A alerts
High impacting Agilent Technologies, Inc. news events
Weekly update
A roundup of the hottest topics
A
News
- Mission Bio's New Translocation Analysis Offers Insights into Critical Safety Assessment for Gene-Edited Cell Products [Yahoo! Finance]Yahoo! Finance
- Single Nucleotide Polymorphism Genotyping Market Global Industry Analysis & Forecast 2018-2028: Pharmaceutical Development Accelerates SNP Genotyping Utilization [Yahoo! Finance]Yahoo! Finance
- Expansion of Organic and Sustainable Agriculture Catapults the Pesticide Detection Market; FMI Analysts Predict Market Valuation to Surpass US$ 3,049.50 million by 2034 [Yahoo! Finance]Yahoo! Finance
- Companion Diagnostics Market is Expected to Reach $13.6 billion | MarketsandMarkets™ [Yahoo! Finance]Yahoo! Finance
- Peptide and Oligonucleotide CDMO Market Size, Outlook: Analysing the 11.5% CAGR and USD 7.40 Billion Projection by 2033 [Yahoo! Finance]Yahoo! Finance
A
Earnings
- 2/27/24 - Beat
A
Sec Filings
- 4/10/24 - Form SC
- 3/27/24 - Form 4
- 3/25/24 - Form 144
- A's page on the SEC website